全文获取类型
收费全文 | 1250篇 |
免费 | 77篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 80篇 |
妇产科学 | 13篇 |
基础医学 | 164篇 |
口腔科学 | 44篇 |
临床医学 | 145篇 |
内科学 | 305篇 |
皮肤病学 | 15篇 |
神经病学 | 79篇 |
特种医学 | 145篇 |
外科学 | 125篇 |
综合类 | 45篇 |
一般理论 | 2篇 |
预防医学 | 48篇 |
眼科学 | 4篇 |
药学 | 71篇 |
肿瘤学 | 56篇 |
出版年
2021年 | 13篇 |
2020年 | 9篇 |
2019年 | 10篇 |
2018年 | 11篇 |
2017年 | 18篇 |
2016年 | 20篇 |
2015年 | 17篇 |
2014年 | 27篇 |
2013年 | 27篇 |
2012年 | 42篇 |
2011年 | 65篇 |
2010年 | 24篇 |
2009年 | 39篇 |
2008年 | 54篇 |
2007年 | 65篇 |
2006年 | 36篇 |
2005年 | 58篇 |
2004年 | 42篇 |
2003年 | 39篇 |
2002年 | 25篇 |
2001年 | 36篇 |
2000年 | 28篇 |
1999年 | 25篇 |
1998年 | 44篇 |
1997年 | 28篇 |
1996年 | 32篇 |
1995年 | 23篇 |
1994年 | 26篇 |
1993年 | 15篇 |
1992年 | 16篇 |
1991年 | 23篇 |
1990年 | 23篇 |
1989年 | 41篇 |
1988年 | 45篇 |
1987年 | 25篇 |
1986年 | 25篇 |
1985年 | 27篇 |
1984年 | 20篇 |
1983年 | 14篇 |
1982年 | 9篇 |
1981年 | 10篇 |
1980年 | 14篇 |
1979年 | 17篇 |
1978年 | 10篇 |
1977年 | 13篇 |
1976年 | 14篇 |
1974年 | 10篇 |
1973年 | 11篇 |
1970年 | 8篇 |
1969年 | 6篇 |
排序方式: 共有1348条查询结果,搜索用时 15 毫秒
1.
Jeremy N Friedman Michael J Rieder Jennifer M Walton Canadian Paediatric Society Acute Care Committee Drug Therapy Hazardous Substances Committee 《Paediatrics & child health》2014,19(9):485-491
Bronchiolitis is the most common reason for admission to hospital in the first year of life. There is tremendous variation in the clinical management of this condition across Canada and around the world, including significant use of unnecessary tests and ineffective therapies. This statement pertains to generally healthy children ≤2 years of age with bronchiolitis. The diagnosis of bronchiolitis is based primarily on the history of illness and physical examination findings. Laboratory investigations are generally unhelpful. Bronchiolitis is a self-limiting disease, usually managed with supportive care at home. Groups at high risk for severe disease are described and guidelines for admission to hospital are presented. Evidence for the efficacy of various therapies is discussed and recommendations are made for management. Monitoring requirements and discharge readiness from hospital are also discussed. 相似文献
2.
CR Valeri G Ragno LE Pivacek R Srey JR Hess LE Lippert F Mettille R Fahie EM O''Neill IO Szymanski 《Transfusion》2002,42(12):1618-1618
3.
4.
5.
6.
Gwendlyn Kollmorgen Gerhard Niederfellner Alexander Lifke Gloria J. Spohn Natascha Rieder Suzana Vega Harring Frieder Bauss Helmut Burtscher Reiner Lammers Birgit Bossenmaier 《Molecular oncology》2013,7(6):1142-1151
CUB-domain-containing-protein-1 (CDCP1) is an integral membrane protein whose expression is up-regulated in various cancer types. Although high CDCP1 expression has been correlated with poor prognosis in lung, breast, pancreas, and renal cancer, its functional role in tumor formation or progression is incompletely understood. So far it has remained unclear, whether CDCP1 is a useful target for antibody therapy of cancer and what could be a desired mode of action for a therapeutically useful antibody. To shed light on these questions, we have investigated the cellular effects of a therapeutic antibody candidate (RG7287). In focus formation assays, prolonged RG7287 treatment prevented the loss of contact inhibition caused by co-transformation of NIH3T3 cells with CDCP1 and Src. In a xenograft study, MCF7 cells stably overexpressing CDCP1 reached the predefined tumor volume faster than the parental MCF7 cells lacking endogenous CDCP1. This tumor growth advantage was abolished by RG7287 treatment. In vitro, RG7287 induced rapid tyrosine phosphorylation of CDCP1 by Src, which was accompanied by translocation of CDCP1 to a Triton X-100 insoluble fraction of the plasma membrane. Triggering these effects required bivalency of the antibody suggesting that it involves CDCP1 dimerization or clustering. However, this initial activation of CDCP1 was only transient and prolonged RG7287 treatment induced internalization and down-regulation of CDCP1 in different cancer cell lines. Antibody stimulated CDCP1 degradation required Src activity and was proteasome dependent. Also in three different xenograft models with endogenous CDCP1 expression RG7287 treatment resulted in significant tumor growth inhibition concomitant with substantially reduced CDCP1 levels as judged by immunohistochemistry and Western blotting. Thus, despite transiently activating CDCP1 signaling, the RG7287 antibody has a therapeutically useful mode of action. 相似文献
7.
8.
9.
10.